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ABSTRACT
Background. On the ﬁrst haemodialysis (HD) day after the 2-
day break in three times a week (3W) in-centre HD, mortality
and hospitalization are higher. If longer HD sessions prescribed
3W is associated with a reduction in these events is unknown.
Methods. HD session length in 19 557 prevalent European in-
centre 3W HD patients participating in the Dialysis
Outcomes and Practice Patterns Study (1998–2011) were
categorized into <200, 200–225, 226–250 or >250min.
Standardized event rates on the ﬁrst (HD1) versus the second
(HD2) HD day after the 2-day break, with supporting Cox
proportional hazards models adjusted for patient and dialysis
characteristics, were generated for all-cause mortality, all-cause
hospitalization, out-of-hospital death and ﬂuid overload
hospitalization.
Results. By comparing HD1 with HD2, increased rates of
all endpoints were observed (all P< 0.002). As HD session
lengthened across the four groups, all-cause mortality per 100
patient-years on the HD1 (23.0, 20.4, 16.4 and 14.6) and HD2
(26.1, 13.3, 13.4 and 12.1) reduced. Similar improvements
were observed for out-of-hospital death but were less marked
for hospitalization endpoints. However, even patients dialysing
>250min were at signiﬁcantly greater risk on HD1 when
compared with their HD2 for out-of-hospital death [hazard ra-
tio (HR) ¼ 2.1, 95% CI 1.0–4.3], all-cause hospitalization
(HR ¼ 1.3, 95% CI 1.2–1.4) and ﬂuid overload hospitalization
(HR¼ 3.2, 95% CI 1.8–6.0).
Conclusions. Despite the association between reduced mortal-
ity across all dialysis days in patients performing longer
sessions, elevated risk on the ﬁrst dialysis day relative to the sec-
ond persists even in patients dialysing 4.5 h 3W.
Keywords: haemodialysis, hospitalization, interdialytic inter-
val, mortality, treatment time
INTRODUCTION
Over 90% of prevalent patients receiving in-centre haemodialy-
sis (HD) for end-stage renal failure receive it three times a week
(3W) [1]. The majority attend HD sessions on Monday,
Wednesday and Friday, or Tuesday, Thursday and Saturday. As
a result, there are two consecutive days without HD treatment
at the end of the dialysis week. Observational data show an as-
sociation between increased mortality and hospitalization on
the first day after this 2-day break from HD, irrespective of
whether this day falls on a Monday or a Tuesday [2–4].
These increases in mortality and hospitalization are often
greater where cardiac disease is the underlying cause.
Postulated mechanisms include fluid overload resulting in the
development of left ventricular hypertrophy and the need to re-
move more fluid during the dialysis session [5–7]. Peak concen-
trations of toxins including potassium [8] increase the risk of
arrhythmias and sudden death manifesting in higher rates of
sudden or out-of-hospital death [3, 9]. The more rapid shifts in
fluid and electrolytes during the first HD session (HD1) of the
week are associated with cardiovascular morbidity and mortal-
ity [10], likely through their promotion of myocardial stunning
[11], arrhythmias [9] and post-dialysis hypotension [12].
VC The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA.
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Suggested interventions for the 2-day break problem worth
exploring include modifying practices within the 3W regime
session such as prescribing longer HD sessions and differing
fluid removal strategies [13], and increasing the number of HD
sessions in a range of formats. The large-scale alteration of dial-
ysis frequency comes with logistical issues, but the practice of
extending dialysis treatment time is more widespread. Longer
treatment times have been associated with better blood pressure
control, improved metabolic parameters, reduced left ventricu-
lar hypertrophy and may facilitate more regular achievement of
‘dry weight’—the patient’s weight in the absence of overhydra-
tion [14–17]. Furthermore, longer sessions have the capacity to
reduce the rate of fluid and potassium movement. These effects
are appealing given the potential mechanisms for the excess
adverse event rates after the 2-day break outlined above.
Existing observational studies show that longer treatment times
are associated with a reduction in mortality and hospitalization
[16]. However, the association between longer treatment times
and increased mortality and hospitalization on the first HD day
of the week has not yet been explored. The study aims to first
confirm the association between the 2-day break (long gap) and
the endpoints of mortality, hospitalization, out-of-hospital
death and hospitalization for heart failure/fluid overload. We
then evaluate the association between longer treatment times
and the risk of events after the 2-day break within the European
in-centre HD patient population.
MATERIALS AND METHODS
Patients and data sources
The Dialysis Outcomes and Practice Patterns Study
(DOPPS) is a prospective cohort study of in-centre prevalent
HD patients conducted across four continents [18, 19]. In this
study, we included data on HD patients from seven European
countries (Belgium, France, Germany, Italy, Sweden, Spain and
the UK) recruited in DOPPS Phases I–IV between 1998 and
2011. Research staff at participating facilities code hospitaliza-
tion using a standardized coding list developed for DOPPS,
which includes diagnosis and procedure codes. Research staffs
use a range of sources to determine these data including patient
notes and discharge summaries. For each 4-month period of
follow-up, more detailed information was collected on the last
HD session including the date of the last collected blood tests.
To assign the dialysis schedule, if the date reported of this HD
session fell on Monday, Wednesday or Friday (Mon/Wed/Fri)
in conjunction with a frequency of 3W, then they were
assigned a Mon/Wed/Fri dialysis schedule. If this date fell on
Tuesday, Thursday and Saturday (Tue/Thu/Sat), then the
schedule was defined in a similar manner. When this fell on a
Sunday or no date was reported, schedules defined from previ-
ous or subsequent 4 month blocks were used. To avoid any day-
of-the-week bias introduced by planned hospitalizations, all
hospitalization analyses were limited to admissions longer than
two nights and excluded hospitalizations coded as routine diag-
nostic tests or physical examinations relating maintenance dial-
ysis care.
The day after the 2-day break (long gap)
Within all analyses, the day after the 2-day break (also
referred to as the long gap) represents the HD1 after the two
consecutive days without HD. This represents Monday in a
patient dialysing on a Mon/Wed/Fri schedule and Tuesday in a
patient dialysing on a Tue/Thu/Sat schedule.
Statistical analyses
Mortality and hospitalization on individual days of the
week. Single event (mortality endpoints) and multiple event
Andersen and Gill [20] (hospitalization endpoints) Cox regres-
sion analyses were used to evaluate the risk [hazard ratio (HR)
and 95% confidence interval (CI)] on each day of the dialysis
week compared with the day of the second HD session (HD2),
censoring changes in dialysis frequency and modality, loss to
follow-up or transfer to a facility not participating in the
DOPPS. HD2 was chosen rather than the whole rest of
the dialysis week because mortality and hospitalization are
higher on the days the patient receives HD than non-HD days.
In illustrative figures, we present the HR of individual days of
the dialysis week compared with the day of the HD2 in Mon/
Wed/Fri patients in order to explore any significant difference
in risk profile betweenMon/Wed/Fri and Tue/Thu/Sat patients.
As both dialysis day of the week and treatment time vary during
the follow-up period, we employed a time-varying approach
that involved representing each individual day of follow-up as
an observation. All analyses presented were stratified by coun-
try, study phase, age and HD schedule and adjusted for sex,
race, 13 comorbid conditions (coronary heart disease, cancer
other than skin, other cardiovascular disease, cerebrovascular
disease, congestive heart failure, diabetes, gastrointestinal bleed-
ing, hypertension, lung disease, neurological disease, psychiatric
disorder, peripheral vascular disease and recurrent cellulitis),
residual kidney function (>200 mL of urine per day at enrol-
ment into DOPPS), body mass index (BMI), dialysis access
blood flow and the time the patient had been receiving renal re-
placement therapy. Stratifying by rather than adjusting for
some variables allows for different baseline hazards to be speci-
fied, which avoids violations of the proportional hazards as-
sumption for these variables. Biochemical data, surrogates of
volume expansion or ultrafiltration rate, were not included in
models as they potentially lie in the causal pathway between
treatment time length and endpoints [21]. All variables with the
exception of residual kidney function and comorbid conditions
were updated if they changed during follow-up. Facility cluster-
ing was taken into account using a robust sandwich covariance
matrix estimator. To address missing covariate data, we per-
formed multiple imputation by chained equations employing
fully conditional specifications, reducing the proportion of
patients with missing covariate data from 19.1% to 0% (detailed
in Supplementary data, Table S1).
Mortality and hospitalization on individual days of the
week by length of dialysis treatment time. In order to ex-
plore whether the relative and absolute increase in events after
the 2-day break were similar across the range of observed treat-
ment time groups, we assessed the mortality and hospitalization
2 J. Fotheringham et al.
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event rates for 3W in-centre HD patients separately. Four
treatment time groups were defined that encompassed the most
commonly prescribed treatment times (presented in brackets):
<200min (180), 200–225min (210), 226–250min (240) and
>250min (270 and 300) per HD session. Event rates were di-
rectly standardized for the age and comorbidity profile of the
largest 226–250min treatment time group [22]. Cox regression
analysis employing the broader range of adjustment variables
detailed above was used to evaluate the risk (HR and 95% CI) of
mortality and hospitalization of the first HD day after the 2-day
break compared with the second HD day, separately for each of
the four treatment time groups. Note that this approach does
not illustrate any effect of treatment time between groups, but
only the risk from the 2-day break within a treatment time
group.
To visualize the overall association between treatment time
and mortality and hospitalization risk, specifically the day after
the 2-day break and across the rest of the dialysis week, we eval-
uated the risk of these endpoints for each day across all four
treatment time groups individually (i.e. 28 separate day/dura-
tion categories) compared with the second dialysis day in the
226–250min group (reference group). These models were strat-
ified and adjusted for the same variables as described above.
Sensitivity analyses. To screen for bias, additional sensitivity
analyses were conducted to examine whether the effect esti-
mates differed from our main results. First, we performed an in-
strumental variable analysis utilizing variation in treatment
time practice across dialysis facilities as a form of pseudoran-
domization that can reduce bias [23]. To ensure that changes in
treatment time immediately prior to mortality or hospitaliza-
tion event did not bias our conclusions regarding treatment
time, we analysed the treatment time from the preceding 4-
month period (a lagged analysis). Second, hypothesizing that
patients may receive short treatment times for palliative rea-
sons, or that shorter treatment times employed in some facilities
would not be generalizable and could introduce bias, we com-
pared patients receiving 200–249min HD treatment time with
those receiving 250min and longer. Finally, we repeated our
hospitalization analyses retaining short inpatient admissions,
and assessed the association between mortality and longer treat-
ment time stratified by the presence of residual kidney function.
These analyses are presented in Supplementary data.
All analyses were performed in STATA 14.2 (Stata Corp.,
College Station, TX, USA).
RESULTS
Study sample
From 21 880 European patients on HD recruited into
EURODOPPS, 19 557 patients with data on treatment
time were receiving in-centre HD and could be assigned a
3W dialysis schedule. The mean follow-up was 18.5months
and 4052 patients died. The distribution of patient characteris-
tics across the four treatment time groups at enrolment into
EURODOPPS is shown in Table 1. Patients dialysing for more
minutes were on average younger, more likely male and had
a greater prevalence of comorbidities.
Mortality and hospitalization on individual days of the
week
Figure 1 shows adjusted HRs and 95% CIs for mortality and
hospitalization across the dialysis week compared with the
HD2 of the week for the two HD schedules separately. The
HD1 (most left in the figures) represents the first dialysis day af-
ter the 2-day break. Colour versions of this and subsequent fig-
ures are available as Supplementary data.
The mortality rate on HD1, the first dialysis day after the 2-
day break was 17.0/100 patient-years compared with 14.0 for
HD2. Variation in mortality by dialysis day of the week was
greater in those dying out of hospital compared with those dy-
ing in hospital (Figure 2A and B). Out-of-hospital deaths
accounted for 24.8% of total deaths, and had greater relative
increases after the 2-day break (5.0 versus 2.8/100 patient-years,
adjusted HR¼ 1.72, 95% CI 1.34–2.20).
Hospitalization rate was generally higher on the days
patients attended for HD, with greatest increases seen on: 1.47
admissions per year after the 2-day break compared with 1.14
per year for HD2 (adjusted HR ¼ 1.25, 95% CI 1.18–1.33).
Although the HR for cardiovascular admissions across the dial-
ysis week was similar to that of all-cause admissions, admissions
for fluid overload/heart failure showed a higher risk after the 2-
day break (Figure 2C and D): 6.4/year versus 2.3/year (adjusted
HR¼ 2.70, 95% CI 2.07–3.52).
Mortality and hospitalization on individual days of the
week by length of dialysis treatment time
Figure 3A shows the mortality and hospitalization event
rates on the first and second HD days of the week, standardized
to the patient characterstics of those receiving 226–250min.
These show a consistent association between reduced mortality
endpoints and longer treatment times on both the first and sec-
ond HD days; however, in patients receiving longer treatment
times, the event rate on HD1 remains higher than that on HD2.
With the exception of mortality in the shortest treatment time
group, all four treatment time groups experienced similar rela-
tive increases in the endpoints on HD1 compared with HD2
(Figure 3B). Longer treatment times had less consistent associa-
tions with reduced hospitalization, but again similar relative
increases after the 2-day break within treatment time groups.
Figure 4 explores the relative risk (HR and 95% CI) of mor-
tality and hospitalization events across each day of the dialysis
week for each of the four treatment time groups compared with
the second dialysis day in the 226–250min group. Notably, the
overall risk of mortality in the shortest treatment time group
was high across all days of the week and showed no 2-day break
effect (Figure 4A). Event rates began to increase on the day
prior to HD1, the second day of the 2-day break.
Sensitivity analyses
The instrumental variable analysis designed to reduce
bias gave comparable results to our presented analyses
(Supplementary data, Figure S1). In the 120 days prior to death,
Longer treatment times and haemodialysis two day break 3
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Table 1. Demography and clinical characteristics of 33W in-centre HD patients at first inclusion in EURODOPPS, stratified by session treatment time
Overall <200 min 200–225 min 226–250 min >250 min P-value
Number of patients, n (%) 19 557 2387 (12.2) 3268 (16.7) 10 241 (52.4) 3661 (18.7)
Age, mean (SD), years 63.8 (14.9) 65.6 (15.5) 65.8 (14.7) 64.0 (14.8) 60.2 (14.3) <0.001
Sex, male, n (%) 11 599 (59.3) 1185 (49.6) 1685 (51.6) 6138 (59.9) 2591 (70.8) <0.001
Ethnicity, Caucasian, n (%) 18 545 (94.8) 2288 (95.6) 3118 (95.4) 9657 (94.3) 3482 (95.1) 0.004
Time on dialysis, mean, months 44.9 33.2 (61.2) 43.4 (64.1) 44.0 (63.0) 56.1 (71.3) <0.001
BMI, mean, kg/m2 25.1 (5.0) 23.8 (4.6) 24.2 (4.5) 25.2 (5.0) 26.7 (5.5) <0.001
Residual kidney function, n (%) 8785 (49) 1403 (63.5) 1453 (47.9) 4441 (47.7) 1488 (44.1) <0.001
Primary renal disease <0.001
Cystic/hereditary/congenital diseases, n (%) 1857 (10.1) 230 (10.2) 295 (9.6) 989 (10.3) 343 (9.9)
Diabetes, n (%) 3843 (20.9) 377 (16.7) 555 (18) 2030 (21.2) 881 (25.4)
Glomerulonephritis, n (%) 3280 (17.9) 333 (14.8) 483 (15.7) 1709 (17.9) 755 (21.8)
Hypertension/large vessel disease, n (%) 3047 (16.6) 397 (17.6) 547 (17.8) 1603 (16.7) 500 (14.4)
Interstitial nephritis/pyelonephritis, n (%) 2211 (12) 324 (14.4) 408 (13.2) 1125 (11.8) 354 (10.2)
Miscellaneous conditions, n (%) 2820 (15.3) 407 (18.1) 596 (19.4) 1419 (14.8) 398 (11.5)
Neoplasms/tumors, n (%) 615 (3.3) 76 (3.4) 83 (2.7) 325 (3.4) 131 (3.8)
Secondary glomerulonephritis/vasculitis, n (%) 700 (3.8) 110 (4.9) 113 (3.7) 373 (3.9) 104 (3)
Comorbid conditions
Diabetes, n (%) 5948 (30.4) 571 (23.9) 877 (26.8) 3166 (30.9) 1334 (36.4) <0.001
Coronary artery disease, n (%) 7775 (39.8) 853 (35.7) 1150 (35.2) 4094 (40.0) 1678 (45.8) <0.001
Heart failure, n (%) 5425 (27.7) 614 (25.7) 783 (24.0) 2894 (28.3) 1134 (31.0) <0.001
Other cardiac, n (%) 7036 (36.2) 806 (33.9) 1114 (34.3) 3744 (36.8) 1372 (37.7) 0.001
Hypertension, n (%) 15 689 (80.8) 1826 (77) 2551 (78.8) 8258 (81.2) 3054 (84) <0.001
Cerebrovascular disease, n (%) 3173 (16.3) 344 (14.5) 557 (17.2) 1699 (16.7) 573 (15.8) 0.025
Peripheral vascular disease, n (%) 5497 (28.3) 559 (23.5) 886 (27.3) 2966 (29.1) 1086 (29.9) <0.001
Diabetes, n (%) 5948 (30.6) 571 (24.1) 877 (27.1) 3166 (31.1) 1334 (36.7) <0.001
Lung disease, n (%) 2401 (12.4) 283 (11.9) 389 (12) 1344 (13.2) 385 (10.6) <0.001
Cancer, n (%) 2718 (14.1) 314 (13.3) 416 (12.9) 1494 (14.7) 494 (13.7) 0.031
GI bleeding, n (%) 1056 (5.5) 141 (6) 160 (4.9) 562 (5.5) 193 (5.3) 0.354
Neurological condition, n (%) 1968 (10.1) 246 (10.4) 310 (9.6) 1065 (10.5) 347 (9.5) 0.267
Psychiatric condition, n (%) 3426 (17.6) 434 (18.3) 569 (17.5) 1774 (17.4) 649 (17.8) 0.775
Recurrent cellulitis, n (%) 1513 (7.8) 141 (5.9) 178 (5.5) 803 (7.9) 391 (10.8) <0.001
Dialysis parameters
Mon/Wed/Fri schedule, n (%) 10 862 (55.5) 1236 (51.8) 1745 (53.4) 5663 (55.3) 2218 (60.6) <0.001
Access type <0.001
Fistula, n (%) 12 618 (70.9) 1354 (66.1) 2137 (72) 6592 (70.3) 2535 (74.3)
Graft, n (%) 1266 (7.1) 134 (6.5) 180 (6.1) 643 (6.9) 309 (9.1)
Catheter, n (%) 3863 (21.7) 555 (27.1) 639 (21.5) 2110 (22.5) 559 (16.4)
Blood ﬂow, mean, mL/min 311.0 (60.8) 300.3 (67.1) 310.9 (56.8) 312.4 (58.8) 314.3 (64.4) <0.001
P-value for differences between treatment time groups. Residual kidney function: <200 mL of urine per day at enrolment into DOPPS.
FIGURE 1: HRs and associated 95% CIs for mortality and hospitalization across the dialysis week in in-centre 3WHD patients: (A) all-cause
mortality by HD schedule (Mon/Wed/Fri and Tue/Thu/Sat regimes); (B) all-cause hospitalization by HD schedule adjusted for age, sex, race,
13 comorbid conditions, BMI, residual kidney function, dialysis access blood ﬂow and time the patient has been receiving renal replacement
therapy, country and DOPPS phase. Reference day: HD2 in Mon/Wed/Fri patients.
4 J. Fotheringham et al.
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/n
d
t/a
d
v
a
n
c
e
-a
rtic
le
-a
b
s
tra
c
t/d
o
i/1
0
.1
0
9
3
/n
d
t/g
fz
0
0
7
/5
3
6
6
9
6
3
 b
y
 U
n
iv
e
rs
ity
 o
f S
h
e
ffie
ld
 u
s
e
r o
n
 2
1
 M
a
rc
h
 2
0
1
9
26.3% of patients changed treatment time. Detailed results us-
ing the treatment time from 120 days prior to death in order to
reduce bias from changes immediately prior to death
(Supplementary data, Figure S2), and results with the shortest
treatment group excluded (leaving 86.6% of the cohort) and
with treatment time dichotomized into <250 and 250min
(Supplementary data, Figure S3) are available in Supplementary
data. These showed a high risk of all endpoints after the 2-day
break which persisted even in the longest treatment time group.
Consistent findings were found following stratification by resid-
ual kidney function (Supplementary data, Figure S4), and with
the inclusion of short-stay hospitalizations (Supplementary
data, Figure S5).
DISCUSSION
The day-of-the-week variation in morbidity and mortality has
been explored in a number of chronic diseases and healthcare
settings [24–28], often focusing on the relationship with (often
unobserved) variable provision of healthcare services. We ex-
plored the effect of the observed interruption in treatment dur-
ing the 2-day break on outcomes and assessed for an
association between extendedHD sessions reduced adverse out-
comes. We confirmed that the HD1 after the 2-day break is as-
sociated with increases in mortality and hospitalization [2–4],
particularly in out-of-hospital death and hospitalization relating
to cardiac failure and fluid overload in both Mon/Wed/Fri and
Tue/Thu/Sat patients. Longer treatment times prescribed 3W
were associated with a decrease in mortality and hospitalization,
both overall and specifically after the 2-day break [16, 29, 30].
Despite greater absolute improvements in mortality on HD1
with longer treatment times compared with other dialysis days,
a relative increase in events on this day compared with the sec-
ond dialysis day was evident even in the longest treatment time
group.
This large cohort study explores an association between a
potential intervention for the 2-day break problem that does
not increase dialysis frequency, thereby maximizing acceptabil-
ity to patients. In those bothered by fluid restriction, 33.5% of
patients would be willing to increase their treatment time by
30min, whereas 19.6% would be willing to add a fourth dialysis
session [31]. By using time-dependent covariates including
treatment time, we were able to take advantage of longitudinal
data collected in EURODOPPS and allow for the real-world
practice of extending treatment time during patients’ dialysis
careers. To explore potential confounding by indication in the
analysis of the effect of treatment times, we employed facility as
an instrumental variable, capitalizing on the variation in practice
across the 189 participating European dialysis facilities to effec-
tively pseudo-randomize patients to different treatment times.
FIGURE 2: HRs and associated 95% CIs for cause-speciﬁc mortality and hospitalization across the dialysis week in in-centre 3WHD
patients: (A) in hospital, (B) out-of-hospital mortality by HD schedule (Mon/Wed/Fri and Tue/Thu/Sat regimes), (C) cardiovascular hospitali-
zation and (D) ﬂuid overload/heart failure hospitalization by dialysis schedule. Adjusted for age, sex, race, 13 comorbid conditions, BMI, resid-
ual kidney function, dialysis access blood ﬂow and time the patient has been receiving renal replacement therapy, country and DOPPS phase.
Reference day: HD2 in Mon/Wed/Fri patients.
Longer treatment times and haemodialysis two day break 5
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Weaknesses of our observational study include confounding
by indication and that despite the methods used residual con-
founding could persist. The data collection schedule in
EURODOPPS only allows variables to change every 4 months,
meaning we were unable to explore changes in these variables
shortly ahead of hospitalization and mortality events in order to
hypothesize mechanisms or develop early warning tools. As
non-adherence is only captured immediately prior to enrol-
ment in DOPPS, we are unable to explore if variable session ad-
herence across the dialysis week is an explanation for the 2-day
break problem.
The nature and size of the 2-day break problem in our study
are in line with previous but not all publications [2–4]. We also
confirmed the overall impact of longer treatment times: a global
analysis of participants in DOPPS found more modest mortal-
ity benefits with longer treatment times overall and specifically
in European participants (HR¼ 0.94, 95% CI 0.91–0.97/30min
extension of treatment time) [16], with other studies using
cross-sectional and time-varying approaches reporting reduc-
tions in mortality more comparable to our study [29, 30]. The
very high risk of mortality in patients receiving HD for
180min per session could be explained by the usually high
cardiovascular morbidity and all-cause mortality risk soon after
the initiation of dialysis when treatment times are generally
shortest [32, 33]. Also, treatment times may be shortened in
patients in whom treatment strategies are entering a more
palliative approach, or in those who become unstable on dialy-
sis due to acute illness, a hypothesis supported by our lagged
analysis (Supplementary data, Figure S2).
Based on our findings, clinicians aiming to fully neutralize
the increase in mortality and hospitalization risk after the 2-day
break might need to consider adding additional HD sessions.
Even with the metabolic and volume benefits associated with
longer treatment times, there is still twice as much time for
waste products and fluid to re-accumulate over the 2-day break
than during the other two interdialytic periods. Any large-scale
change in either session frequency or treatment time would
have an impact on policy surrounding the common 6 day open-
ing of HD facilities and on overall dialysis capacity: of the 110
HD facilities participating in DOPPS Phase IV (2009–11), only
13 were open on both a Saturday and a Sunday. Half of facilities
currently operate three dialysis shifts per day or more on some
of the days they open, meaning extended hours (4.5 h) could
not easily be offered to all patients without opening the unit for
>16 h a day with early starts and late finishes for patients as a
consequence. High serum potassium prior to the 2-day break
has been shown to correlate with increased hospitalization over
this period specifically [34], and the new pharmacological
agents for potassium offer possible non-dialysis interventions.
A study of 1678 arrythmias experienced in 44 of 66 patients
participating in the Monitoring in Dialysis trial showed the
highest arrhythmia rate immediately prior to and during the
FIGURE 3: (A) Standardized event rates for mortality and hospitalization endpoints on the ﬁrst and second HD days of the dialysis week and
(B) the HR of the ﬁrst HD day compared with the second according to per session HD treatment time in 3W in-centre HD patients.
Adjusted for age, sex, race, 13 comorbid conditions, residual kidney function, BMI, dialysis access blood ﬂow and time the patient has been re-
ceiving renal replacement therapy, country, DOPPS phase and HD schedule.
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first session after the 2-day break, and that the use of cooled di-
alysate (<37C) halved the overall event rate [35].
In conclusion, despite demonstrating an association between
extended HD treatment times and a reduction in mortality and
hospitalization, we showed the increased risk on the first HD day
compared with the second persisted even in those patients re-
ceiving HD for 4.5 h per session three times a week. Future re-
search should aim to address proposed mechanisms outside the
3W paradigm, understand the benefits and risks of more fre-
quent dialysis regimes in light of inconsistent observational and
interventional study findings [36–38], and develop patient level
and ideally HD session-level risk tools using more granular data
to trigger an intervention. A solution for the 2-day break prob-
lem that is effective in preventing adverse events, individualized
at a patient level, widely acceptable and cost effective, is needed.
SUPPLEMENTARY DATA
Supplementary data are available at ndt online.
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